(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.05%) $79.04
(0.16%) $1.935
(0.87%) $2 331.00
(0.77%) $26.96
(1.02%) $964.60
(-0.01%) $0.933
(-0.13%) $11.02
(-0.08%) $0.798
(0.06%) $93.51
4 days till quarter result
(bmo 2024-05-05)
Expected move: +/- 0.00%
2.89% KRW 189 000
Live Chart Being Loaded With Signals
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea...
Stats | |
---|---|
Volumen de hoy | 0.00 |
Volumen promedio | 643 909 |
Capitalización de mercado | 41 211.45B |
EPS | KRW0 ( 2024-02-29 ) |
Próxima fecha de ganancias | ( KRW1 008.85 ) 2024-05-05 |
Last Dividend | KRW0 ( N/A ) |
Next Dividend | KRW0 ( N/A ) |
P/E | 44.68 |
ATR14 | KRW175.92 (0.09%) |
Volumen Correlación
Celltrion, Inc. Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Celltrion, Inc. Correlación - Moneda/Commodity
Celltrion, Inc. Finanzas
Annual | 2023 |
Ingresos: | KRW2 176.43B |
Beneficio Bruto: | KRW2 176.43B (100.00 %) |
EPS: | KRW3 658.73 |
FY | 2023 |
Ingresos: | KRW2 176.43B |
Beneficio Bruto: | KRW2 176.43B (100.00 %) |
EPS: | KRW3 658.73 |
FY | 2022 |
Ingresos: | KRW2 283.97B |
Beneficio Bruto: | KRW1 032.70B (45.22 %) |
EPS: | KRW3 894.00 |
FY | 2021 |
Ingresos: | KRW1 911.60B |
Beneficio Bruto: | KRW1 101.42B (57.62 %) |
EPS: | KRW4 302.16 |
Financial Reports:
No articles found.
Celltrion, Inc.
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico